glp-1 obesity drug updates today U.S. Rate Drops as Use of Weight Loss Drugs Surges | National News GLP-1 Targeted Peptide Weight Loss
Description
Compound selection should be driven by demonstrated brain exposure rather than commercial prominence
Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes
Chen C, Zheng H, Xu J, Shi X, Li F, Wang X
Each studies was identified as low, high or unclear risk of bias based on the following items: the statement of randomization, blinding, details of withdrawals and dropouts, generation of random numbers, and concealment of allocation
Bottom line: Shotsy correlates your symptoms with your medication curve to surface patterns
